Pharma Focus Europe

Carl Zeiss Meditec and Precise Bio Announce Partnership in the Development and Commercialization of Tissue-Based Implants for Ophthalmology

Tuesday, July 19, 2022

Carl Zeiss Meditec, Precise Bio, partnership, fabricated corneal tissue, transplants, endothelial keratoplasty, natural lenticule transplants, keratoconus, vision correction, investment, funding, cornea transplant products, worldwide commercialization rights, cataract, corneal refractive workflow solutions, treatment options, patient care, ophthalmology, 4D bio-fabrication platform, breakthrough solutions, eyesight recovery, engineering, biomaterials, cell technology, bioengineering, 3D printing, single-cell resolution, spatial accuracy, organoid constructs, tissue engineering, clinical use, reproducibility, quality control, cost-effective, ophthalmological pipeline, retinal implant, age-related macular degeneration, successful results, animal models, global markets, human cells, natural materials, anatomical structure, tissue components, therapeutic needs.

magazine-slider-img
Thermo Fisher Scientific - mRNA ServicesWorld Orphan Drug Congress 2024World Vaccine Congress Europe 2024Advanced Therapies USA 2024
cytiva